Related Experiment Video

Updated: May 20, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis

Joseph L Schuller1, Matthew Zipse, Thomas Crawford

  • 1Section of Cardiac Electrophysiology, University of Colorado, Denver, Colorado, USA.

Journal of Cardiovascular Electrophysiology
|July 21, 2012
PubMed

Insights

Nearly one-third of cardiac sarcoidosis patients with an implantable cardioverter defibrillator (ICD) received appropriate therapies for ventricular arrhythmias. Ventricular dysfunction and heart failure predict these ICD therapies in cardiac sarcoidosis patients.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Sarcoidosis Research

Background:

  • Cardiac sarcoidosis (CS) is a condition where implantable cardioverter defibrillators (ICDs) are used for sudden cardiac death prevention.
  • Limited data exist on the rates and characteristics of ICD therapies in CS patients.

Purpose of the Study:

  • To determine the incidence and characteristics of ICD therapies in patients with cardiac sarcoidosis.
  • To identify predictors of ICD therapies in this specific patient population.

Main Methods:

  • A cohort study involving patients with CS and ICDs across three institutions.
  • Comparison with historical control data from clinical trials on ICD therapy rates.
  • Analysis of patient data for appropriate and inappropriate ICD therapies and associated clinical factors.

Main Results:

  • Out of 112 CS subjects, 32.1% received appropriate ICD therapies for ventricular tachyarrhythmias (VT) over a mean follow-up of 29.2 months.
  • VT storm occurred in 14.2% of subjects; inappropriate therapies occurred in 11.6%.
  • Predictors for appropriate therapies included left ventricular ejection fraction <55%, right ventricular dysfunction, and symptomatic heart failure.

Conclusions:

  • Approximately one-third of CS patients with ICDs experience appropriate therapies, likely due to myocardial inflammation and subsequent scarring.
  • Left or right ventricular dysfunction are significant adjusted predictors of ICD therapies in this cohort.
Abstract

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...